AVDL vs. VASGX

In the year-to-date period, AVDL achieves a -18.74% return, which is significantly lower than VASGX's 4.51% return. Over the past 10 years, AVDL has underperformed VASGX with an annualized return of -5.25%, while VASGX has yielded a comparatively higher 6.81% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Avadel Pharmaceuticals plc (AVDL) and Vanguard LifeStrategy Growth Fund (VASGX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current AVDL Sharpe Ratio is -0.66, which is lower than the VASGX Sharpe Ratio of 1.17. The chart below compares the historical Sharpe Ratios of AVDL and VASGX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

AVDL has not paid dividends to shareholders, while VASGX's dividend yield for the trailing twelve months is around 2.34%.

The maximum AVDL drawdown since its inception was -97.50%, which is greater than VASGX's maximum drawdown of -51.16%. Use the drawdown chart below to compare losses from any high point for AVDL and VASGX. For additional features, visit the drawdowns tool.

Avadel Pharmaceuticals plc (AVDL) has a higher volatility of 15.54% compared to Vanguard LifeStrategy Growth Fund (VASGX) at 2.48%. This indicates that AVDL's price experiences larger fluctuations and is considered to be riskier than VASGX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.